Every Form 4 that ZEO SCIENTIFIX INC (ZEOX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZEOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZEOX filings page.
Zeo ScientifiX, Inc. reported stock option awards to a major holder and related entity. The filing shows grants of options under the company’s 2021 Equity Incentive Plan, exercisable at an exercise price of $1.67 per share and expiring on June 10, 2036.
Footnotes explain that the options were issued to Greyt Ventures, LLC, a principal stockholder and consultant owned by a trust for which Wendy Grey is trustee. One grant vests upon achieving performance milestones, while another vested in full at the grant date, and both are exercisable on a cashless basis with anti-dilutive features tied to large future issuances.
Zeo ScientifiX, Inc. reported that CEO, CFO and 10% owner Ian T. Bothwell received two grants of stock options on June 10, 2026. Each grant covers 625,000 options to buy common stock at an exercise price of $1.67 per share.
The first grant vested in full on the grant date and is exercisable on a cashless basis for ten years under the company’s 2021 Equity Incentive Plan. The second grant also covers 625,000 options, vests upon achievement of specified performance milestones, is exercisable cashless for up to ten years, and is described as antidilutive for future transactions issuing 10% or more of fully diluted common shares. These are compensation-related awards, not open‑market share purchases.
Zeo ScientifiX, Inc. reported that Chief Medical Officer George Craig Shapiro received two stock option awards. Each grant covers 625,000 options on common stock at an exercise price of $1.67 per share, dated June 10, 2026.
One grant vests in full as of the grant date and is exercisable on a cashless basis for ten years under the 2021 Equity Incentive Plan. The other vests upon specified performance milestones and is also exercisable cashless for ten years once vested, and is described as antidilutive for future transactions issuing at least 10% of common stock on a fully diluted basis.
Zeo ScientifiX, Inc. director Bretz Charles Luther received a grant of stock options to buy 80,000 shares of common stock. The options have an exercise price of $1.67 per share, were fully vested on the June 10, 2026 grant date, and expire on June 10, 2031. Following this award, he holds stock options covering 80,000 underlying shares as direct derivative holdings, reflecting equity-based compensation rather than an open-market trade.
Zeo ScientifiX, Inc. reported an insider equity award involving Greyt Ventures, LLC, a 10% owner. On January 14, 2026, Greyt Ventures received 175,000 shares of Zeo ScientifiX common stock as a grant of restricted shares at a stated price of $0 per share under the company’s 2021 Equity Incentive Plan.
The restricted shares vest in two equal tranches: 50% on the eighth-month anniversary of the grant date and the remaining 50% on the twelfth-month anniversary. Following this grant, Greyt Ventures indirectly beneficially owned 425,000 shares of Zeo ScientifiX common stock. The filing notes these securities were issued to Greyt Ventures, LLC, which is owned by a trust for which Ms. Wendy Grey serves as trustee.
Zeo ScientifiX, Inc. reported an insider equity award for its CEO, CFO and director Ian T. Bothwell. On 01/14/2026, he received 175,000 shares of common stock at a price of $0 per share as a grant of restricted stock under the company’s 2021 Equity Incentive Plan. These shares vest in two equal parts, with 50% vesting on the 8th month anniversary of the grant date and the remaining 50% vesting on the 12th month anniversary. Following this transaction, Bothwell beneficially owned 915,094 shares of Zeo ScientifiX common stock held directly.
Zeo ScientifiX, Inc. reported that Chief Medical Officer and director George Craig Shapiro received a grant of 175,000 shares of common stock on 01/14/2026. The filing shows this as an acquisition at a price of $0 per share, reflecting a restricted stock award under the company’s 2021 Equity Incentive Plan.
According to the terms, the restricted shares vest 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary. Following this equity grant, Shapiro beneficially owns 578,021 shares of Zeo ScientifiX common stock in direct ownership.